Neurocrine Biosciences | NBIX - Ebitda


Neurocrine Biosciences reported $193.3M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Prothena USD -39.53M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Repligen USD 40.01M 469K Mar/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Teva Pharmaceutical Industries USD 1.06B 582M Mar/2026
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xoma USD 2.52M 7.98M Jun/2024